NeuroBo Pharmaceuticals Receives First Site Institutional Review Board Approval For Its Phase 2a Clinical Trial Evaluating DA-1241 For The Treatment Of NASH
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals has received the first site Institutional Review Board approval for its Phase 2a clinical trial evaluating DA-1241 for the treatment of NASH.
August 04, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroBo Pharmaceuticals' Phase 2a clinical trial for DA-1241 has received its first site approval, which could potentially accelerate the development and eventual market availability of the treatment for NASH.
The approval of the first site for NeuroBo's Phase 2a clinical trial is a significant step in the development of DA-1241 for NASH treatment. This could potentially lead to faster completion of the trial, quicker regulatory approval, and earlier market availability, all of which could positively impact NeuroBo's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100